Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Top Cited Papers
- 28 October 2002
- journal article
- clinical trial
- Published by Springer Nature in Leukemia
- Vol. 16 (11) , 2190-2196
- https://doi.org/10.1038/sj.leu.2402741
Abstract
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.Keywords
This publication has 31 references indexed in Scilit:
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 casesLeukemia, 2002
- Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinaseOncogene, 2001
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCRLeukemia, 1999
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- The P-loop — a common motif in ATP- and GTP-binding proteinsTrends in Biochemical Sciences, 1990